These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8300045)

  • 1. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment.
    Laron Z; Klinger B
    Horm Res; 1993; 40(1-3):16-22. PubMed ID: 8300045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.
    Klinger B; Jensen LT; Silbergeld A; Laron Z
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):423-9. PubMed ID: 8959080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism.
    Laron Z; Anin S; Klipper-Aurbach Y; Klinger B
    Lancet; 1992 May; 339(8804):1258-61. PubMed ID: 1349669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome.
    Bisker-Kassif O; Kauli R; Lilos P; Laron Z
    Obes Res Clin Pract; 2014; 8(1):e55-62. PubMed ID: 24548577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I.
    Laron Z; Klinger B; Blum WF; Silbergeld A; Ranke MB
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):301-4. PubMed ID: 1373347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism.
    Laron Z; Klinger B; Jensen LT; Erster B
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):145-50. PubMed ID: 1934530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or Laron syndrome.
    Brat O; Ziv I; Klinger B; Avraham M; Laron Z
    Horm Res; 1997; 47(2):45-8. PubMed ID: 9030966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term IGF-I treatment of children with Laron syndrome increases adiposity.
    Laron Z; Ginsberg S; Lilos P; Arbiv M; Vaisman N
    Growth Horm IGF Res; 2006 Feb; 16(1):61-4. PubMed ID: 16442822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three year IGF-I treatment of children with Laron syndrome.
    Klinger B; Laron Z
    J Pediatr Endocrinol Metab; 1995; 8(3):149-58. PubMed ID: 8521188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes.
    Wilton P
    Acta Paediatr Suppl; 1992 Sep; 383():137-42. PubMed ID: 1281024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum prolactin in patients with Laron-type dwarfism: effect of insulin-like growth factor I.
    Silbergeld A; Klinger B; Schwartz H; Laron Z
    Horm Res; 1992; 37(4-5):160-4. PubMed ID: 1490658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome).
    Savage MO; Blum WF; Ranke MB; Postel-Vinay MC; Cotterill AM; Hall K; Chatelain PG; Preece MA; Rosenfeld RG
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1465-71. PubMed ID: 7505286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
    Laron Z
    Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome.
    Laron Z
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4397-404. PubMed ID: 10599694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prismatic cases: Laron syndrome (primary growth hormone resistance) from patient to laboratory to patient.
    Laron Z
    J Clin Endocrinol Metab; 1995 May; 80(5):1526-31. PubMed ID: 7744997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism.
    Laron Z; Klinger B; Erster B; Anin S
    Lancet; 1988 Nov; 2(8621):1170-2. PubMed ID: 2903379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The little women of Loja--growth hormone-receptor deficiency in an inbred population of southern Ecuador.
    Rosenbloom AL; Guevara Aguirre J; Rosenfeld RG; Fielder PJ
    N Engl J Med; 1990 Nov; 323(20):1367-74. PubMed ID: 2233903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.
    Laron Z; Kauli R
    Growth Horm IGF Res; 2016 Jun; 28():53-6. PubMed ID: 26307357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism.
    Laron Z; Klinger B; Erster B; Silbergeld A
    Acta Endocrinol (Copenh); 1989 Oct; 121(4):603-8. PubMed ID: 2800930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment.
    Carel JC; Chaussain JL; Chatelain P; Savage MO
    Diabetes Metab; 1996 Jul; 22(4):251-6. PubMed ID: 8767171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.